je.st
news
Tag: study drug
Keryx says anemia drug succeeds in study of kidney patients
2016-03-29 13:57:33| Biotech - Topix.net
Keryx Biopharmaceuticals Inc on Tuesday said its drug to treat iron deficiency anemia in chronic kidney disease patients not yet requiring dialysis met the goals of a late stage clinical trial, potentially paving the way for an expanded approval of the treatment. In the 16-week study of 234 patients with moderate to severe kidney disease, 52 percent of those who received Keryx's ferric citrate saw their hemoglobin levels rise by at least 1 gram per deciliter of blood during the trial.
Tags: study
drug
patients
kidney
Study Finds Multiple Myeloma Drug 'Promising'
2015-12-07 20:50:57| Biotech - Topix.net
Merck & Co's immunotherapy Keytruda led to a high response rate for patients with the blood cancer multiple myeloma when added to standard therapy in a small, early stage trial, according to data presented on Monday. The Phase I study tested Keytruda in combination with Celgene's Revlimid and the corticosteroid dexamethasone in patients whose disease had progressed after they had already received several other treatments, including several who were not helped by previous treatment with Revlimid.
Tags: study
multiple
drug
finds
Merck continuing study of cholesterol drug in new class
2015-11-13 19:27:25| Biotech - Topix.net
Merck & Co. will continue a huge patient study of an experimental cholesterol medicine - the last one standing in a once-promising new drug class - after an independent monitoring committee recommended the study continue.
Tags: class
study
drug
continuing
GSK Heart Drug Flops In Study, Shingles Vaccine On Track
2015-10-28 08:39:04| Biotech - Topix.net
An experimental heart drug from GlaxoSmithKline failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its pipeline of new medicines. Losmapimod was being assessed as a treatment to reduce the risk of further cardiovascular problems after heart attacks, but it failed to show the hoped-for benefits and GSK said the result did not support investment in a larger second part of the study.
Study finds key GSK-Theravance lung drug didn't extend lives
2015-09-09 01:33:31| Biotech - Topix.net
A closely watched study of GlaxoSmithKline plc's Breo Ellipta respiratory treatment failed to prove that it extends patients' lives, denying the drugmaker a much-needed marketing edge in its most lucrative - but declining - medicine category. It was a disappointing deja vu for the British drugmaker, which previously failed to prove the same benefit for its much older respiratory treatment Advair, long the company's top seller with revenue of $8.3 billion as recently as 2013.